Rosa announces that Douglas Chung, Engineer at Rosa, will present at the MathWorks SimBiology User Forum on October 27th in Bellevue, WA. Rosa & Co. developed the RateCalculator, a MATLAB script that calculates a set of reaction rates connected to a species of interest from an existing SimBiology model and plots the resulting values in an organized and informative way. The talk entitled "Computing and Graphing Fluxes to Facilitate QSP/PhysioPD™ Model Development and Calibration" demonstrates the use of this script in the context of a PhysioPD Platform to highlight both the mechanics of using it, and its utility in developing QSP/PhysioPD models. (Abstract)
Rosa & Co. LLC today announced their participation and poster presentation at ACoP7 to be held in Bellevue, WA on October 23-26, 2016 . Rosa’s Dr. Christina Friedrich, Chief Engineer, PhysioPD™ will present a poster on Monday, October 24th, 2016 at 7:30am to 9:30am. The poster entitled “A Quantitative Systems Pharmacology Platform of Brain and Serum Progranulin (PGRN) to Investigate Targets in Frontotemporal Dementia (FTD)” will demonstrate that the PGRN PhysioPD Research Platform has proven useful to simulate the effects of modulating different targets and model drug effects on increasing PGRN for the treatment of FTD.
Rosa & Co.’s Chief Engineer, PhysioPD™, Dr. Christina Friedrich was recently interviewed for MedicalResearch.com, which publishes exclusive interviews with medical researchers published in major and specialty medical journals. The interview, entitled “Rosa & Co. Develop PhysioMap To Advance Drug Development Programs”, discusses Elan and Rosa’s collaboration in the development of a Synuclein PhysioMap®, a graphical model architecture to support hypothesis generation and testing. This collaboration provided insight into the function of alpha-synuclein in Parkinson's disease.
Rosa announces that Dr. Meghan Pryor, Engineer at Rosa, presented at the MathWorks SimBiology User Forum on September 20th in Boston, MA. Rosa & Co. developed the RateCalculator, a MATLAB script that calculates a set of reaction rates connected to a species of interest from an existing SimBiology model and plots the resulting values in an organized and informative way. The talk entitled "Computing and Graphing Fluxes to Facilitate QSP/PhysioPD™ Model Development and Calibration" demonstrates the use of this script in the context of a PhysioPD Platform to highlight both the mechanics of using it, and its utility in developing QSP/PhysioPD models. (Abstract).
Rosa announces that Dr. Christina Friedrich, Chief Engineer, PhysioPD at Rosa, will present a poster at the 4th World Parkinson Congress on Friday September 23, 2016 at 11:30am to 1:30pm. The poster entitled "Development of a qualitative systems pharmacology model to support hypothesis generation and testing for Parkinson's disease" will demonstrate that the research team identified key biological uncertainties and hypotheses and recommended focused laboratory experiments to gain a better understanding of synuclein function in Parkinson's disease (Press release, poster).
Rosa’s Dr. Michael Weis co-authored an encore poster presentation at the 2016 World Conference on Pharmacometrics (WCoP) entitled: “The International Society of Pharmacometrics’ (ISoP) Special Interest Group (SIG) on Quantitative Systems Pharmacology (QSP): Developing a Community and Advancing a Field”. The poster describes the work of the ISoP QSP SIG to advance the development and utilization of safe and efficacious medicines through the application of QSP.
Rosa announces that Dr. Mike Reed, Chief Scientist, PhysioPD™ at Rosa, will present a poster at the 2016 World Conference on Pharmacometrics (WCoP) on August 24th, 2016 at 12:45 pm – 1:15 pm in Brisbane, Australia. The poster entitled “Application of a quantitative systems pharmacology (QSP) model to evaluate xCT inhibition as a target for central nervous system diseases” will demonstrate that development of a Central Nervous System PhysioPD Research Platform is an illustrative research case of the key role that PhysioPD modeling can play in providing quantitative integration of internal and external knowledge, elucidating mechanistic insight, and supporting decisions in early stage drug discovery. (Press Release, poster).
Rosa’s Dr. Michael Weis co-authored a poster at the Population Approach Group, Europe (PAGE) conference entitled: “The International Society of Pharmacometrics’ (ISoP) Special Interest Group (SIG) on Quantitative Systems Pharmacology (QSP): Developing a Community and Advancing a Field”. The poster describes the work of the ISoP QSP SIG to advance the development and utilization of safe and efficacious medicines through the application of QSP.
Rosa's Christina Friedrich, Chief Engineer, PhysioPD™ and MathWorks’ Fulden Buyukozturk, Technical Evangelist, will present a joint webinar on July 13th, 2016 at 10:00 am and 2:00pm EDT. QSP/PhysioPD approaches aim to predict the safety and therapeutic impact of a drug by quantifying the dynamics of its interactions with underlying pathophysiology in order to guide and support drug development. This webinar will use a rheumatoid arthritis (RA) PhysioPD™ Research Platform developed by Rosa & Co to illustrate the utility of key features of MATLAB and SimBiology in exploring pharmaceutical research questions. (press release)
Rosa's Sharan A. Pagano, Senior Vice President of Scientific Alliances will present at the 7th Annual Shanghai Symposium on Clinical & Pharmaceutical Solutions through Analysis (CPSA Shanghai 2016) on Friday, April 22, 2016. The conference focuses on the current industrial landscape and the global need to bring products to market faster. Ms. Pagano’s talk, entitled “Mechanistic Physiological PhysioPD™ Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) approach” will focus on the process of creating and conducting research using PhysioPD Platforms to drive scientific innovation in the pharmaceutical industry. PhysioPD Platforms are QSP models designed with multidisciplinary client team input. The PhysioPD research approach is planned to impact client decisions and has been successful across many therapeutic indications.(press release, slides)
Rosa & Co. LLC participated 2016 Roche QSP Methodology Workshop held on February 4 & 5th, 2016 in Basel, Switzerland. Dr. Christina Friedrich, Chief Engineer at Rosa, recently published an article on QSP model qualification, and participated in the workshop that brought together key opinion leaders from industry and academia to make a substantive contribution toward even broader implementation of QSP. The workshop capitalized on the group’s accumulated experience and applications to review and discuss evolving methodologies in the field. (press release)
Rosa & Co.’s Chief Engineer, Dr. Christina Friedrich published an article, “Model Qualification Method for Mechanistic Physiological QSP Models to Support Model-Informed Drug Development” in the CPT: Pharmacometrics & Systems Pharmacology Journal. QSP is being used increasingly by innovative R&D organizations as a powerful research approach that combines available data with scientific knowledge and engineering approaches to facilitate better understanding of biological systems, to improve decision-making, and to reduce risk and increase efficiency in drug discovery and development. Dr. Friedrich’s tutorial draws on years of experience to generate a rigorous, systematic, and broadly applicable Model Qualification Method (MQM) to ensure that QSP models are well-qualified and fit for their intended purposes. The MQM addresses questions of model relevance, scope, uncertainty, biological variability, and use of data, so that model-informed research can proceed with confidence. (Article) (press release)
Rosa & Co. LLC presented a poster at the 2015 Roche Pharma Research and Early Development (pRED) Symposium, held on November 2-3rd, 2015 in New York City. Rosa’s poster, entitled “Model qualification approaches for quantitative systems pharmacology (QSP) and mechanistic physiological models”, was presented by Dr. Christina Friedrich, Chief Engineer at Rosa. The poster compared several recently proposed model qualification approaches, including Rosa’s Model Qualification Method (MQM), to identify common themes and analyze differences. The symposium, entitled “Increasing Drug Development Success: Understanding Drug-Disease Interactions through Quantitative Systems Pharmacology”, was designed to bring together key global leaders in QSP to explore ways to leverage the interface of theoretical and experimental pharmacology to improve drug development efficiency. (press release)
Rosa & Co. LLC, today announced that Dr. Christina Friedrich, Chief Engineer, will lead a workshop at the QSP Congress Meeting on October 20th, 2015 in Boston, MA. The conference focuses on the uses and benefits of QSP in pharmaceutical drug development. Dr. Friedrich’s workshop is entitled ”Using Mechanistic Physiological Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) Approach”. She will discuss the use of a systematic approach to model qualification, Rosa’s Model Qualification Method (MQM), which ensures that a model is developed and judged fit for use. Case studies and model examples will illustrate the MQM process. (press release)
Rosa & Co. LLC today announced it has five posters and a tutorial scheduled to be presented during the sixth American Conference on Pharmacometrics (ACoP6) in Crystal City, VA, October 4-7, 2015. The poster presentations will describe research and a range of results including the application of PhysioPD Platforms to clinical trial design and translational research. The posters will be presented with Sanofi, Bristol Myers Squibb, Stiefel, (a GSK company) and by Rosa & Co. The MathWorks, Inc. tutorial uses a Rheumatoid Arthritis PhysioPD Platform developed by Rosa to illustrate the use of SimBiology and MATLAB to streamline QSP workflows. (Press release)
Rosa & Co. LLC today announced a co-marketing agreement with MathWorks, developer of mathematical computing software and maker of MATLAB, SimBiology and Simulink. The agreement between MathWorks and Rosa will provide drug development professionals examples of how to address real world challenges using state-of-the-art software tools and proven QSP modeling approaches. (press release)
Rosa & Co. LLC today announced its pleasure to be a premier sponsor for the Discovery on Target Conference in Boston, MA on September 21-24th, 2015. The Quantitative Systems Pharmacology Tract at the conference is designed as a knowledge and opinion exchange forum, highlighting strategy and implementation of QSP from early discovery to early clinical development in the pharmaceutical industry. In addition to its sponsorship, Rosa will be presenting a talk and teaching a short course as part of the QSP program. (press release}
Rosa & Co. LLC is currentlly seeking a leader with a strong scientific background to support client business development activities. Reporting to the Senior Vice President of Scientific Alliances, the ideal candidate will partner with Clients Services on existing accounts and provide research and support for new account opportunities. (Announcement, pdf)
Rosa & Co. LLC, is pleased to announce the initiation of a multi-year Research Agreement with Sanofi Global R&D to provide Rosa’s market-leading PhysioPD services to worldwide Sanofi affiliates. The collaboration provides Sanofi a competitive research and development advantage and greater access to the extensive depth and breadth of Rosa’s expertise. Rosa’s agreement with Sanofi further extends Rosa’s presence as the global market leader in the Quantitative Systems Pharmacology field. (Press release)
Dr. Ananth Kadambi delivered the Keynote Address at the QSP Congress on April 28, 2015 in Basel, Switzerland. He discussed the philosophical and practical roles of QSP in the scientific process, common R&D applications, and key aspects of QSP market adoption. Additionally, on April 29, 2015, Dr. Mike Reed presented a significant case study that covered creating and performing research with PhysioPD™ Research Platforms. Rosa also participated in two panel discussions during the conference on current and future applications of QSP. (Press release)
Bristol-Myers Squibb and Rosa will present a poster describing a Virtual Systems Pharmacology (ViSP) web-based environment at the ASCPT 2015 Annual Meeting in New Orleans, LA. The poster, entitled “Virtual Systems Pharmacology (ViSP) flexible web-based environment for running large multi-scale models” will be presented by Tarek Leil, Ph.D. during the Quantitative Systems Pharmacology Pre-Conference Poster Session on Tuesday, March 3, 2015, 12:45 PM - 1:45 PM and during the Late-Breaking and Encore Poster Session I on Thursday, March 5th, 2015 from 4:30 – 6:30 PM at the Hyatt Regency, Elite Hall Foyer. (Abstract)(Press release)
Bristol-Myers Squibb and Rosa will present a poster describing a quantitative systems pharmacology approach for immuno-oncology drug development at the ASCPT 2015 Annual Meeting in New Orleans, LA. The poster, entitled “Development of a quantitative systems pharmacology platform to support translational research and clinical development in immuno-oncology” will be presented by Brian Schmidt, Ph.D. during the Quantitative Systems Pharmacology Pre-Conference Poster Session on Tuesday, March 3, 2015, 12:45 PM - 1:45 PM and during the Late-Breaking and Encore Poster Session II on Friday, March 6th, 2015 from 4:30 – 6:30 PM at the Hyatt Regency, Elite Hall Foyer. (Abstract)(Press release)
Dr. Ananth Kadambi will be speaking at the 19th North American ISSX Meeting/29th JSSX Meeting at the Hilton, San Francisco, on Wednesday, October 22, 2014 at 9:00 - 11:30 a.m. His talk is entitled “Application of Quantitative System Pharmacology Modeling to Translational Research”.
Dr Christina Friedrich will be speaking at the American Conference on Pharmacometrics (ACoP) in Las Vegas NV, on Monday, October 13th at 3-5 pm. Her talk is entitled “Quantitative Systems Pharmacology (QSP) informs in vitro to in vivo translation for PCSK9 antibody”.
Rosa's Dr. Gordi will be speaking to the Bio2Device Group in Sunnyvale, CA, on Aug. 26, 8:30 A.M. In his talk, entitled "Drug Development in silico: Models and Their Utility", Dr. Gordi will discuss the various types of study models and their application to the drug development process. (Abstract)
MedImmune and Rosa presented a poster, entitled "Quantitative Systems Pharmacology Modeling to Evaluate Clinical Response of an anti-TNFa/anti-Ang2 Bispecific Antibody in Rheumatoid Arthritis" at the American Society of Clinical Phamacology and Therapeutics Conference in Atlanta, GA on March 20, 2014. The poster describes a quantitative systems pharmacology model (PhysioPD™ Model) that represents the pathophysiology of rheumatoid arthritis, designed to address the target-mediated drug disposition kinetics of a bispecific antibody directed against TNFa and angiotensin 2. (Abstract)
Amgen and Rosa presented a poster, entitled "Pharmacology Model to Characterize the Effect of Blinatumomab in Patients With Adult B-Precursor Acute Lymphoblastic Leukemia" at the American Society of Clinical Phamacology and Therapeutics Conference in Atlanta, GA on March 18 (Biologics pre-conference) and 21, 2014. The poster describes key questions addressed with a quantitative systems pharmacology model (PhysioPD™ Model) that represents the pathophysiology of B-Precursor Acute Lymphoblastic Leukemia and the effect of blinatumomab, a T-cell activator that leads to B-cell death.
Rosa is pleased to announce the appointment of Ananth Kadambi, PhD, as Senior Vice President, PhysioPD, to manage their rapidly-expanding business in Japan and Asia. Dr. Kadami comes to Rosa from Evidera, where he served as as the Director of Modeling and Simulation. Previous to that, Dr. Kadambi rose from Team Leader to Vice President at Entelos Holdings, Inc. (Press release)
Rosa is pleased to announce the acquisition of the consulting service business of Entelos Holdings, Inc., which conducts mechanistic, physiologic, in silico modeling projects for customers in pharmaceutical research and development. The acquisition, which closed January 7, 2014, further extends Rosa’s presence in quantitative systems pharmacology and modeling and simulation research services and adds to Rosa's already significant expertise in cardiovascular, immunology, and metabolism biology, and human nutrition. (Press release)
Rosa is pleased to announce it has established an alliance with the KressWorks Foundation to develop a Ewing’s Sarcoma PhysioPD Research Platform, a quantitative model of the physiologic and pharmacologic mechanisms involved in Ewing’s Sarcoma. (Press release)
Rosa is pleased to announce that Katherine Kudrycki, Ph.D. has joined Rosa as Principal Scientist. In addition, Rosa has expanded its engineering team. (Press release)
Rosa will be presenting a talk entitled “Application of a physiologically-based model incorporating drug-specific PK modules to support optimization of GLP-1 receptor agonist combination therapies for type 2 diabetes” at the AAPS meeting on November 10-14, 2013 in San Antonio, Texas. (Abstract, Press release)
As the Expertise Partner, Rosa will be presenting the plenary session presentation entitled “Accomplishments and Challenges in Systems Pharmacology” at the Integrating Pharmacometrics Summit in Munich, Germany, Oct 21-23 2013. Dr. Ron Beaver will discuss the volume of experience and the wide-use of the systems pharmacology approach; what decisions in drug development can be supported; how we think about “value” and how we judge “quality”; dealing with scepticism and setting projects up for success; and how we apply this approach systematically to our pipeline. (Press Release)
The American Association of Pharmaceutical Scientists Bay Area Discussion Group will meet on Sept 12, 2013. Rosa's Dr. Toufigh Gordi will present a talk entitled "Models and Their Utility in the Drug Development Process" (Flyer)
Rosa offers a free download of its Model Qualification Method (“MQM”), published in the White Paper, “Facilitating Drug Discovery and Development with Mechanistic Physiological Models that are ‘Fit for Purpose’”, to facilitate the broader adoption and use of mechanistic, physiologic models in pharmaceutical research and development. Rosa is also offering MQM-focused educational activities in 2012 in the EU and US. On March 2, 2012, there will be a seminar sponsored by an industry group in the San Francisco Bay Area (www.bapkpd.org); workshops will be offered on March 27 – 29, 2012 at the 3rd Annual World PK/PD Summit, in Boston (pkpd-summit.com) and on April 1 – 4, 2012 at the 5th Annual EFMC Short Course on Medicinal Chemistry, in Leiden, The Netherlands. (Press Release)